Cyril Barinka
Principal Investigator
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
Tubulin C‐terminal tails undergo diverse post‐translational modifications that regulate microtubule interactions with motors and severing enzymes. TTLL11, a member of the tubulin tyrosine ligase‐like (TTLL) family, uniquely catalyzes glutamate addition to the terminal α‐carboxyl group of both α‐ and β‐primary tubulin tails. This linear C‐terminal glutamylation enables the rescue of truncated tubulin variants and may support re‐entry into the modification cycle. TTLL11 substrate specificity is determined by terminal residue identity rather than tubulin isotype. These findings expand the tubulin code and raise new questions about how linear and branched glutamylation are differentially recognized by microtubule‐associated proteins.
Year:
2026
Microtubules (MTs) undergo diverse posttranslational modifications that regulate their structural and functional properties. Among these, polyglutamylation—a dominant and conserved modification targeting unstructured tubulin C-terminal tails—plays a pivotal role in defining the tubulin code. Here, we describe a mechanism by which tubulin tyrosine ligase–like 11 (TTLL11) expands and diversifies the code. Cryo–electron microscopy revealed a unique bipartite MT recognition strategy wherein TTLL11 binding and catalytic domains engage adjacent MT protofilaments. Biochemical and cellular assays identified previously uncharacterized polyglutamylation patterns, showing that TTLL11 directly extends the primary polypeptide chains of α- and β-tubulin in vitro, challenging the prevailing paradigms emphasizing lateral branching. Moreover, cell-based and in vivo data suggest a cross-talk between polyglutamylation and the detyrosination/tyrosination cycle likely linked to the TTLL11-mediated elongation of the primary α-tubulin chain. These findings unveil an unrecognized layer of complexity within the tubulin code and offer mechanistic insights into the molecular basis of functional specialization of MT cytoskeleton.
Year:
2025
Year:
2025
Prostate cancer (PCa) ranks as the second leading cause of cancer-related deaths among men in the United States. Prostate-specific membrane antigen (PSMA) represents a well-established biomarker of PCa, and its levels correlate positively with the disease progression, culminating at the stage of metastatic castration-resistant prostate cancer. Due to its tissue-specific expression and cell surface localization, PSMA shows superior potential for precise imaging and therapy of PCa. Antibody-based immunotherapy targeting PSMA offers the promise of selectively engaging the host immune system with minimal off-target effects. Here we report on the design, expression, purification, and characterization of a bispecific engager, termed 5D3-CP33, that efficiently recruits macrophages to the vicinity of PSMA-positive cancer cells mediating PCa death. The engager was engineered by fusing the anti-PSMA 5D3 antibody fragment to a cyclic peptide 33 (CP33), selectively binding the Fc gamma receptor I (FcγRI/CD64) on the surface of phagocytes. Functional parts of the 5D3-CP33 engager revealed a nanomolar affinity for PSMA and FcγRI/CD64 with dissociation constants of K D = 3 nM and K D = 140 nM, respectively. At a concentration as low as 0.3 nM, the engager was found to trigger the production of reactive oxygen species by U937 monocytic cells in the presence of PSMA-positive cells. Moreover, flow cytometry analysis demonstrated antibody-dependent cell-mediated phagocytosis of PSMA-positive cancer cells by U937 monocytes when exposed to 0.15 nM 5D3-CP33. Our findings illustrate that 5D3-CP33 effectively and specifically activates monocytes upon PSMA-positive target engagement, resulting in the elimination of tumor cells. The 5D3-CP33 engager can thus serve as a promising lead for developing new immunotherapy tools for the efficient treatment of PCa.
Year:
2025
Retinitis pigmentosa (RP) is a hereditary disorder caused by mutations in more than 70 different genes including those that encode proteins important for pre-mRNA splicing. Most RP-associated mutations in splicing factors reduce either their expression, stability or incorporation into functional splicing complexes. However, we have previously shown that two RP mutations in PRPF8 (F2314L and Y2334N) and two in SNRNP200 (S1087L and R1090L) behaved differently, and it was still unclear how these mutations affect the functions of both proteins. To investigate this in the context of functional spliceosomes, we used iCLIP in HeLa and retinal pigment epithelial (RPE) cells. We found that both mutations in the RNA helicase SNRNP200 change its interaction with U4 and U6 snRNAs. The significantly broader binding profile of mutated SNRNP200 within the U4 region upstream of the U4/U6 stem I strongly suggests that its activity to unwind snRNAs is impaired. This was confirmed by FRAP measurements and helicase activity assays comparing mutant and WT protein. The RP variants of PRPF8 did not affect snRNAs, but showed a reduced binding to pre-mRNAs, which resulted in the slower splicing of introns and altered expression of hundreds of genes in RPE cells. This suggests that changes in the expression and splicing of specific genes are the main driver of retinal degeneration in PRPF8-linked RP.
Year:
2025
Year:
2025
Year:
2025
SULF1, a human extracellular heparan 6-O-endosulfatase isoform 1, plays a critical role in embryonic development and cancer progression by modulating the 6-O-sulfation of heparan sulfate proteoglycans. However, limited recombinant protein production has hindered structural and functional characterization. To address this issue, we optimized SULF1 expression in HEK293F and HEK293T cells. We achieved yields of 2.2 mg/L of culture media after Ni2+-affinity purification of greater than 80% purity, representing a substantial improvement compared to the reported expression systems. We demonstrated that co-expression of sulfatase-modifying factor 1 in this expression system is essential for enhancing SULF1 enzymatic activity, which depends on conversion of active site cysteine to Cα-formylglycine and the presence of a Ca2+ ion. We further showed that a marine fucosylated chondroitin sulfate polymer isolated from the sea cucumber Holothuria floridana inhibits SULF1 enzymatic activity with IC50 of 0.05 ± 0.006 μg/mL and 0.07 ± 0.008 μg/mL for the GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA and 4-methylumbelliferyl sulfate substrates, respectively. Kinetic analysis revealed a mixed-mode inhibition, characterized by alterations in Vmax at all inhibitor concentrations and Km at high inhibitor concentrations. Efficient SULF1 production also enabled us to develop specific monoclonal antibodies, which confirmed SULF1 expression in the stroma of head and neck squamous cell cancer tissues. Collectively, this study provides an efficient workflow for the production of active human SULF1, investigates SULF1 inhibitors, and characterizes anti-SULF1 monoclonal antibodies, which will support further studies of this enzyme in various pathophysiological conditions.
Year:
2025
Immune cells can significantly influence the therapeutic outcomes of anti-cancer therapies. Particularly, tumor-associated macrophages (TAMs) mainly exhibit an anti-inflammatory M2-like phenotype and are well recognized for their pro-tumoral activity, which supports tumor growth and suppresses anti-tumor immune responses. Nonetheless, TAMs exhibit remarkable plasticity, allowing for their reprogramming toward an anti-tumoral M1-like phenotype through targeted epigenetic modulations. Our group has previously reported several highly selective histone deacetylase 6 inhibitors (HDAC6is) that promote the polarization of TAMs toward the M1-like phenotype while suppressing the M2-like pro-tumoral phenotype. Despite this promising discovery, the current HDAC6is face several drawbacks, including efficacy at micromolar concentrations, which results in poor isoform selectivity and potential off-target effects. To address these limitations, we developed an advanced screening pipeline for HDAC6is on macrophage functions, and the antitumor benefits associated with their treatment, alone or in combination with anti-PD1 in the immunocompetent SM1 murine melanoma model. Based on an in silico screening of 980 HDAC6is derivatives and a macrophage-based screening described previously, we identified two candidates, SM-05-947 and SM-06-09, that showed superior properties compared to their parent molecules. The screening included the determination of cytotoxicity, specificity of HDAC inhibition, and the modulation of macrophage phenotype. Using bone marrow-derived macrophages, the treatment-associated changes in macrophage functions were characterized. Following dose determination, we studied their antitumor effects on SM1 melanoma tumors when administered as a single agent or combined with anti-PD1 antibodies. The tumor microenvironment was further characterized by immunotyping using flow cytometry, CyToF, and sc-RNA sequencing. The functional assays provided further evidence of increased phagocytosis of tumor cells and improved antigen cross-presentation with HDAC6 inhibition. Specifically, the presence of SIINFEKL peptide in the context of MHC class I in macrophages treated with HDAC6is showed a significant increase in antigen presentation by M1 macrophages. Administration of SM-06-09 and SM-05-947 as a single agent significantly reduced tumor growth when compared to the vehicle group. The two combination groups of HDAC6is and anti-PD1 antibodies further significantly improved these antitumor effects, as observed by flow cytometry, CyToF, and sc-RNA sequencing analysis. In conclusion, these findings provide valuable insights and pave the way toward the development of next-generation HDAC6is with maximum efficiency, minimal toxicity, and enhanced anticancer potential of TAMs. Citation Format: Nithya Gajendran, Manasa Suresh, David Quiceno, Sonia Sebaoui, Xintang Li, Marie Durr, Sebastian J. Marquez Rodriguez, Mario A. Noboa, Sruthi Mohan, Barbora Havlinova, Julia Kudlacova, Annie Heuer, Satish Kumar Reddy Noonepalle, Cyril Barinka, Duncan J. Wardrop, Alejandro Villagra. Advancing cancer immunotherapy through the development of a novel selective HDAC6 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4216.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (15)
Michaela Müller-McNicoll
W2 Professor
Goethe University Frankfurt
Wolfgang Sippl
Professor
Martin Luther University Halle-Wittenberg
Alejandro Villagra
Associate Professor
Georgetown University
Vitor H. Pomin
Associate Professor of Pharmacognosy
University of Mississippi
Duncan Wardrop
Associate Professor
University of Chicago
Lucia Motlová
-
Finn Kristian Hansen
University of Bonn
Dmitri Artemov
Professor
Johns Hopkins University
Konstantinos Tripsianes
Group Leader
Středoevropský technologický institut
Jürgen Graf
Heidelberg University
Jana Balounova
Imunology Unit head
Institute of Molecular Genetics
Sudath Hapuarachchige
Assistant Professor of Radiology and Radiological Science
Johns Hopkins University School of Medicine
Zsofia Kutil
Czech Academy of Sciences, Institute of Hydrodynamics
Ivan Šnajdr
Institute of Organic Chemistry and Biochemistry
Radoslav Goldman
Professor
Georgetown University
Make your next move.
Prepare your application
Review drafts before you send them.